| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Azetidines | 12 | 2021 | 722 | 4.37 | Why? |
| Sulfonamides | 12 | 2021 | 1294 | 2.90 | Why? |
| Purines | 12 | 2021 | 816 | 2.67 | Why? |
| Trastuzumab | 6 | 2018 | 108 | 2.29 | Why? |
| Pyrazoles | 12 | 2021 | 1791 | 1.91 | Why? |
| Biosimilar Pharmaceuticals | 4 | 2018 | 205 | 1.40 | Why? |
| Antineoplastic Agents, Phytogenic | 2 | 2017 | 183 | 1.20 | Why? |
| Carcinogenesis | 3 | 2018 | 236 | 1.20 | Why? |
| Breast Neoplasms | 10 | 2018 | 3633 | 1.13 | Why? |
| Janus Kinase Inhibitors | 4 | 2021 | 682 | 1.02 | Why? |
| Pyrimidines | 2 | 2021 | 1557 | 0.98 | Why? |
| Gene Expression Regulation, Neoplastic | 4 | 2018 | 1014 | 0.92 | Why? |
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2020 | 76 | 0.83 | Why? |
| Aminopyridines | 1 | 2020 | 121 | 0.80 | Why? |
| Neoplasms | 12 | 2021 | 17251 | 0.77 | Why? |
| Oncogenes | 2 | 2017 | 23 | 0.76 | Why? |
| Neoplastic Cells, Circulating | 3 | 2018 | 68 | 0.74 | Why? |
| Morpholines | 1 | 2020 | 351 | 0.74 | Why? |
| Capsicum | 1 | 2017 | 9 | 0.71 | Why? |
| Capsaicin | 1 | 2017 | 19 | 0.71 | Why? |
| Chromosomal Instability | 1 | 2017 | 9 | 0.70 | Why? |
| Quackery | 1 | 2017 | 11 | 0.69 | Why? |
| Smoking Prevention | 1 | 2019 | 116 | 0.69 | Why? |
| Publishing | 2 | 2017 | 990 | 0.67 | Why? |
| Janus Kinases | 1 | 2021 | 414 | 0.67 | Why? |
| Caloric Restriction | 1 | 2017 | 56 | 0.66 | Why? |
| Glycyrrhiza | 1 | 2017 | 141 | 0.63 | Why? |
| Scientific Misconduct | 1 | 2017 | 101 | 0.60 | Why? |
| Fraud | 1 | 2017 | 116 | 0.59 | Why? |
| Colonic Neoplasms | 1 | 2019 | 295 | 0.58 | Why? |
| Cell Cycle Proteins | 1 | 2017 | 297 | 0.57 | Why? |
| Piperidines | 1 | 2021 | 795 | 0.56 | Why? |
| Cigarette Smoking | 1 | 2019 | 337 | 0.56 | Why? |
| Crowding | 1 | 2020 | 731 | 0.55 | Why? |
| Receptor, ErbB-2 | 4 | 2018 | 267 | 0.54 | Why? |
| Drug Resistance, Neoplasm | 1 | 2018 | 447 | 0.54 | Why? |
| Peer Review, Research | 1 | 2017 | 407 | 0.51 | Why? |
| Energy Metabolism | 1 | 2017 | 451 | 0.48 | Why? |
| Colorectal Neoplasms | 4 | 2019 | 1884 | 0.47 | Why? |
| Stomach Neoplasms | 1 | 2018 | 477 | 0.47 | Why? |
| Biomarkers, Tumor | 5 | 2021 | 1314 | 0.47 | Why? |
| Acute Lung Injury | 1 | 2020 | 904 | 0.47 | Why? |
| Neoplasm Proteins | 1 | 2017 | 501 | 0.46 | Why? |
| Fasting | 1 | 2017 | 555 | 0.45 | Why? |
| Antiviral Agents | 6 | 2021 | 41703 | 0.43 | Why? |
| Protein Kinase Inhibitors | 2 | 2020 | 1585 | 0.43 | Why? |
| Adenocarcinoma | 1 | 2017 | 651 | 0.41 | Why? |
| Enzyme Inhibitors | 1 | 2021 | 1881 | 0.40 | Why? |
| Liver | 3 | 2021 | 4007 | 0.40 | Why? |
| Evidence-Based Medicine | 3 | 2017 | 3228 | 0.39 | Why? |
| Proteomics | 1 | 2020 | 2481 | 0.38 | Why? |
| Antineoplastic Agents | 6 | 2018 | 3550 | 0.35 | Why? |
| MicroRNAs | 3 | 2018 | 1787 | 0.35 | Why? |
| Forkhead Transcription Factors | 1 | 2009 | 231 | 0.35 | Why? |
| Membrane Proteins | 1 | 2018 | 1733 | 0.34 | Why? |
| Neoadjuvant Therapy | 4 | 2018 | 554 | 0.34 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 1573 | 0.32 | Why? |
| Cytokines | 5 | 2021 | 15010 | 0.32 | Why? |
| Lung Neoplasms | 3 | 2019 | 3228 | 0.32 | Why? |
| Sarcoma, Kaposi | 1 | 2007 | 97 | 0.31 | Why? |
| Plant Extracts | 1 | 2017 | 1514 | 0.31 | Why? |
| ErbB Receptors | 2 | 2017 | 320 | 0.29 | Why? |
| Ubiquitin-Protein Ligases | 2 | 2018 | 249 | 0.29 | Why? |
| Drug Repositioning | 2 | 2020 | 5683 | 0.28 | Why? |
| Artificial Intelligence | 1 | 2020 | 3543 | 0.28 | Why? |
| Periodicals as Topic | 1 | 2017 | 1492 | 0.27 | Why? |
| Genetic Variation | 2 | 2018 | 3919 | 0.27 | Why? |
| Interleukin-17 | 1 | 2009 | 602 | 0.27 | Why? |
| Neoplasm Staging | 4 | 2018 | 1999 | 0.26 | Why? |
| Humans | 61 | 2021 | 930598 | 0.24 | Why? |
| T-Lymphocytes, Regulatory | 1 | 2009 | 698 | 0.24 | Why? |
| Intestinal Neoplasms | 1 | 2021 | 42 | 0.22 | Why? |
| Syk Kinase | 1 | 2020 | 32 | 0.22 | Why? |
| Plants, Medicinal | 2 | 2017 | 622 | 0.21 | Why? |
| Xenograft Model Antitumor Assays | 2 | 2018 | 274 | 0.21 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 2007 | 533 | 0.21 | Why? |
| Neuroendocrine Tumors | 2 | 2021 | 241 | 0.21 | Why? |
| Mice, Nude | 2 | 2018 | 340 | 0.21 | Why? |
| Circulating MicroRNA | 1 | 2021 | 123 | 0.21 | Why? |
| Phytotherapy | 2 | 2017 | 743 | 0.21 | Why? |
| Spheroids, Cellular | 1 | 2020 | 124 | 0.20 | Why? |
| Pneumonia, Viral | 10 | 2021 | 243684 | 0.20 | Why? |
| Immunological Synapses | 1 | 2018 | 6 | 0.20 | Why? |
| Toll-Like Receptor 2 | 1 | 2020 | 198 | 0.20 | Why? |
| Hyphae | 1 | 2018 | 22 | 0.19 | Why? |
| DNA Breaks, Double-Stranded | 1 | 2018 | 17 | 0.19 | Why? |
| Ataxia Telangiectasia Mutated Proteins | 1 | 2018 | 48 | 0.18 | Why? |
| Drug Evaluation, Preclinical | 2 | 2021 | 3347 | 0.18 | Why? |
| Cell Degranulation | 1 | 2018 | 130 | 0.18 | Why? |
| Drug Resistance, Viral | 1 | 2005 | 1083 | 0.18 | Why? |
| Topotecan | 1 | 2018 | 62 | 0.18 | Why? |
| Tumor Microenvironment | 2 | 2018 | 264 | 0.18 | Why? |
| Lipopeptides | 1 | 2020 | 229 | 0.18 | Why? |
| Tumor Cells, Cultured | 1 | 2018 | 254 | 0.18 | Why? |
| Epirubicin | 1 | 2017 | 21 | 0.18 | Why? |
| G1 Phase Cell Cycle Checkpoints | 1 | 2017 | 26 | 0.18 | Why? |
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 334 | 0.17 | Why? |
| Precursor Cells, B-Lymphoid | 1 | 2017 | 12 | 0.17 | Why? |
| Mucin-1 | 1 | 2020 | 277 | 0.17 | Why? |
| Taxoids | 1 | 2017 | 45 | 0.17 | Why? |
| Transformation, Genetic | 1 | 2017 | 35 | 0.17 | Why? |
| Female | 27 | 2021 | 380317 | 0.17 | Why? |
| Mitosis | 1 | 2017 | 43 | 0.17 | Why? |
| Poly-ADP-Ribose Binding Proteins | 1 | 2017 | 47 | 0.17 | Why? |
| Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.17 | Why? |
| Plant Roots | 1 | 2017 | 108 | 0.17 | Why? |
| Coronavirus Infections | 9 | 2021 | 253789 | 0.17 | Why? |
| Cell Size | 1 | 2017 | 106 | 0.17 | Why? |
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 112 | 0.17 | Why? |
| MCF-7 Cells | 1 | 2017 | 199 | 0.17 | Why? |
| Tumor Suppressor Proteins | 1 | 2018 | 165 | 0.17 | Why? |
| Chemotherapy, Adjuvant | 2 | 2017 | 606 | 0.16 | Why? |
| DNA Helicases | 1 | 2018 | 203 | 0.16 | Why? |
| Russia | 1 | 2021 | 989 | 0.16 | Why? |
| Biomedical Research | 1 | 2017 | 5270 | 0.16 | Why? |
| 14-3-3 Proteins | 1 | 2017 | 55 | 0.16 | Why? |
| Cell Line, Tumor | 4 | 2018 | 3608 | 0.16 | Why? |
| Transforming Growth Factor beta1 | 1 | 2018 | 204 | 0.16 | Why? |
| Fluorouracil | 1 | 2017 | 169 | 0.16 | Why? |
| Platelet Activation | 1 | 2021 | 660 | 0.16 | Why? |
| Betacoronavirus | 8 | 2020 | 204454 | 0.16 | Why? |
| Ribonucleoproteins | 1 | 2017 | 151 | 0.16 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.16 | Why? |
| Administration, Intranasal | 1 | 2020 | 1132 | 0.16 | Why? |
| Stromal Cells | 1 | 2016 | 105 | 0.15 | Why? |
| Aspergillus fumigatus | 1 | 2018 | 239 | 0.15 | Why? |
| Venlafaxine Hydrochloride | 1 | 2015 | 30 | 0.15 | Why? |
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2015 | 15 | 0.15 | Why? |
| Pharmacovigilance | 1 | 2020 | 501 | 0.15 | Why? |
| Hot Flashes | 1 | 2015 | 20 | 0.15 | Why? |
| Cell Lineage | 1 | 2017 | 241 | 0.15 | Why? |
| Animals | 12 | 2020 | 78931 | 0.15 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 8811 | 0.15 | Why? |
| Doxorubicin | 1 | 2018 | 313 | 0.15 | Why? |
| Practice Guidelines as Topic | 1 | 2020 | 15421 | 0.15 | Why? |
| Leukemia | 2 | 2018 | 598 | 0.15 | Why? |
| Glioblastoma | 1 | 2018 | 187 | 0.15 | Why? |
| Cell-Derived Microparticles | 1 | 2016 | 134 | 0.15 | Why? |
| Adverse Drug Reaction Reporting Systems | 1 | 2020 | 694 | 0.15 | Why? |
| Carcinoembryonic Antigen | 1 | 2016 | 140 | 0.15 | Why? |
| Cyclophosphamide | 1 | 2017 | 387 | 0.15 | Why? |
| Histones | 1 | 2018 | 371 | 0.14 | Why? |
| Febrile Neutropenia | 1 | 2017 | 179 | 0.14 | Why? |
| Aspergillosis | 1 | 2018 | 264 | 0.14 | Why? |
| Gene Editing | 1 | 2018 | 330 | 0.14 | Why? |
| Ferrets | 1 | 2020 | 1201 | 0.14 | Why? |
| DNA Damage | 1 | 2017 | 285 | 0.14 | Why? |
| Cell Death | 1 | 2017 | 536 | 0.14 | Why? |
| Genome, Human | 1 | 2018 | 400 | 0.14 | Why? |
| Gene Expression Profiling | 2 | 2021 | 3788 | 0.14 | Why? |
| Hormones | 1 | 2014 | 66 | 0.14 | Why? |
| Receptors, Cytoplasmic and Nuclear | 1 | 2014 | 67 | 0.14 | Why? |
| Autoantigens | 1 | 2017 | 388 | 0.14 | Why? |
| Killer Cells, Natural | 2 | 2018 | 2093 | 0.14 | Why? |
| Cell Adhesion Molecules | 1 | 2017 | 472 | 0.14 | Why? |
| Spain | 3 | 2021 | 15545 | 0.13 | Why? |
| Antineoplastic Agents, Immunological | 2 | 2018 | 830 | 0.13 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2009 | 4545 | 0.13 | Why? |
| Delivery of Health Care | 1 | 2020 | 15909 | 0.13 | Why? |
| Mice | 5 | 2020 | 21357 | 0.13 | Why? |
| CD56 Antigen | 2 | 2018 | 193 | 0.13 | Why? |
| RNA, Untranslated | 1 | 2014 | 140 | 0.13 | Why? |
| Leukocytes | 1 | 2020 | 1046 | 0.12 | Why? |
| Fibroblasts | 1 | 2017 | 839 | 0.12 | Why? |
| United States Food and Drug Administration | 1 | 2020 | 1276 | 0.12 | Why? |
| Hepatectomy | 1 | 2016 | 276 | 0.12 | Why? |
| Risk Assessment | 5 | 2020 | 25439 | 0.12 | Why? |
| Drug Design | 1 | 2005 | 2627 | 0.12 | Why? |
| Mastectomy | 1 | 2017 | 536 | 0.12 | Why? |
| Neoplastic Stem Cells | 1 | 2013 | 120 | 0.12 | Why? |
| Anti-HIV Agents | 1 | 2005 | 2209 | 0.12 | Why? |
| Treatment Outcome | 7 | 2021 | 51732 | 0.12 | Why? |
| GPI-Linked Proteins | 2 | 2017 | 317 | 0.11 | Why? |
| Ovarian Neoplasms | 1 | 2017 | 465 | 0.11 | Why? |
| Aged, 80 and over | 9 | 2021 | 88759 | 0.11 | Why? |
| Decision Support Techniques | 1 | 2019 | 903 | 0.11 | Why? |
| Asthma | 2 | 2020 | 4383 | 0.11 | Why? |
| Antibodies, Monoclonal | 2 | 2018 | 8041 | 0.11 | Why? |
| Frail Elderly | 1 | 2021 | 1427 | 0.11 | Why? |
| Male | 16 | 2021 | 367725 | 0.11 | Why? |
| History, 20th Century | 1 | 2017 | 1282 | 0.11 | Why? |
| Lipids | 1 | 2018 | 1079 | 0.11 | Why? |
| Pandemics | 10 | 2021 | 389249 | 0.11 | Why? |
| Pancreatic Neoplasms | 1 | 2018 | 609 | 0.11 | Why? |
| Signal Transduction | 3 | 2018 | 7207 | 0.11 | Why? |
| Anti-Inflammatory Agents | 2 | 2020 | 6153 | 0.11 | Why? |
| Aged | 12 | 2021 | 215776 | 0.11 | Why? |
| RNA-Binding Proteins | 1 | 2018 | 1022 | 0.10 | Why? |
| RNA | 1 | 2018 | 1278 | 0.10 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.10 | Why? |
| Smoking Cessation | 1 | 2019 | 826 | 0.10 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 1261 | 0.10 | Why? |
| History, 21st Century | 1 | 2017 | 1849 | 0.10 | Why? |
| Disabled Persons | 1 | 2021 | 1152 | 0.10 | Why? |
| HIV-1 | 1 | 2005 | 3365 | 0.10 | Why? |
| Antiretroviral Therapy, Highly Active | 2 | 2007 | 952 | 0.10 | Why? |
| Extracellular Vesicles | 1 | 2016 | 607 | 0.10 | Why? |
| Survival Rate | 3 | 2021 | 9206 | 0.10 | Why? |
| Double-Blind Method | 2 | 2018 | 5988 | 0.09 | Why? |
| Adult | 11 | 2021 | 244371 | 0.09 | Why? |
| China | 3 | 2020 | 50654 | 0.09 | Why? |
| Basic Reproduction Number | 1 | 2020 | 2676 | 0.09 | Why? |
| Patient Safety | 2 | 2021 | 4885 | 0.09 | Why? |
| Drug Delivery Systems | 1 | 2018 | 1365 | 0.09 | Why? |
| Proportional Hazards Models | 1 | 2021 | 6543 | 0.09 | Why? |
| Sequence Analysis, RNA | 1 | 2017 | 2290 | 0.09 | Why? |
| Combined Modality Therapy | 1 | 2017 | 3395 | 0.09 | Why? |
| Point-of-Care Testing | 1 | 2021 | 2782 | 0.09 | Why? |
| Gestational Trophoblastic Disease | 1 | 2006 | 8 | 0.08 | Why? |
| Consensus | 2 | 2019 | 6345 | 0.08 | Why? |
| Antibody Formation | 1 | 2021 | 4038 | 0.08 | Why? |
| Antigens, CD19 | 1 | 2007 | 98 | 0.08 | Why? |
| Middle Aged | 11 | 2021 | 270681 | 0.08 | Why? |
| Europe | 2 | 2021 | 12702 | 0.08 | Why? |
| Serologic Tests | 1 | 2021 | 4359 | 0.08 | Why? |
| Uterine Neoplasms | 1 | 2006 | 70 | 0.08 | Why? |
| Antirheumatic Agents | 1 | 2020 | 3023 | 0.07 | Why? |
| Clinical Decision-Making | 1 | 2019 | 3755 | 0.07 | Why? |
| Inpatients | 1 | 2021 | 5161 | 0.07 | Why? |
| HIV Fusion Inhibitors | 1 | 2005 | 80 | 0.07 | Why? |
| Lymphoma, AIDS-Related | 1 | 2003 | 13 | 0.07 | Why? |
| Immunization, Passive | 1 | 2020 | 10067 | 0.07 | Why? |
| Mortality | 1 | 2021 | 7132 | 0.07 | Why? |
| Comorbidity | 4 | 2021 | 34796 | 0.07 | Why? |
| Patient Selection | 1 | 2018 | 4560 | 0.07 | Why? |
| Liver Neoplasms | 1 | 2016 | 1666 | 0.07 | Why? |
| Receptors, IgG | 1 | 2007 | 578 | 0.06 | Why? |
| Phenotype | 3 | 2020 | 4037 | 0.06 | Why? |
| Reverse Transcriptase Inhibitors | 1 | 2005 | 309 | 0.06 | Why? |
| T-Lymphocytes, Cytotoxic | 1 | 2007 | 552 | 0.06 | Why? |
| Brain | 1 | 2020 | 5133 | 0.06 | Why? |
| Virus Internalization | 1 | 2021 | 7921 | 0.06 | Why? |
| Up-Regulation | 2 | 2021 | 2249 | 0.06 | Why? |
| Antigens, CD | 1 | 2007 | 984 | 0.06 | Why? |
| Gene Expression Regulation | 1 | 2014 | 4020 | 0.06 | Why? |
| HIV Protease Inhibitors | 1 | 2005 | 434 | 0.06 | Why? |
| Fever | 1 | 2018 | 7795 | 0.05 | Why? |
| Contact Tracing | 1 | 2020 | 8448 | 0.05 | Why? |
| Mutation | 2 | 2018 | 12376 | 0.05 | Why? |
| Neoplasm Recurrence, Local | 2 | 2018 | 1063 | 0.05 | Why? |
| Students | 1 | 2019 | 5255 | 0.05 | Why? |
| Lymphoma, Non-Hodgkin | 1 | 2003 | 403 | 0.05 | Why? |
| Age Factors | 1 | 2021 | 21039 | 0.05 | Why? |
| Prospective Studies | 2 | 2021 | 43301 | 0.05 | Why? |
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2018 | 35 | 0.05 | Why? |
| Prognosis | 4 | 2018 | 32490 | 0.05 | Why? |
| HIV Infections | 1 | 2005 | 11620 | 0.05 | Why? |
| Multivariate Analysis | 2 | 2007 | 5440 | 0.05 | Why? |
| DNA, Fungal | 1 | 2018 | 95 | 0.05 | Why? |
| High-Intensity Focused Ultrasound Ablation | 1 | 2018 | 19 | 0.05 | Why? |
| Introns | 1 | 2018 | 112 | 0.05 | Why? |
| Intestine, Small | 1 | 2021 | 336 | 0.04 | Why? |
| Therapeutic Equivalency | 1 | 2018 | 64 | 0.04 | Why? |
| Codon, Terminator | 1 | 2018 | 72 | 0.04 | Why? |
| Drug Liberation | 1 | 2018 | 141 | 0.04 | Why? |
| Risk Factors | 4 | 2021 | 71621 | 0.04 | Why? |
| Coordination Complexes | 1 | 2018 | 84 | 0.04 | Why? |
| Erlotinib Hydrochloride | 1 | 2017 | 48 | 0.04 | Why? |
| Gene Amplification | 1 | 2017 | 85 | 0.04 | Why? |
| Health Status Indicators | 1 | 2021 | 341 | 0.04 | Why? |
| International Agencies | 1 | 2018 | 202 | 0.04 | Why? |
| Protein Transport | 1 | 2018 | 487 | 0.04 | Why? |
| Hospital Mortality | 1 | 2021 | 22087 | 0.04 | Why? |
| Indicators and Reagents | 1 | 2018 | 183 | 0.04 | Why? |
| Gadolinium | 1 | 2018 | 318 | 0.04 | Why? |
| Hyperthermia, Induced | 1 | 2018 | 106 | 0.04 | Why? |
| Biomarkers | 1 | 2020 | 23361 | 0.04 | Why? |
| RNA, Guide | 1 | 2018 | 269 | 0.04 | Why? |
| Social Isolation | 1 | 2017 | 5932 | 0.04 | Why? |
| Optical Imaging | 1 | 2018 | 197 | 0.04 | Why? |
| Tissue Distribution | 1 | 2018 | 483 | 0.04 | Why? |
| Th2 Cells | 1 | 2020 | 680 | 0.04 | Why? |
| Quinazolines | 1 | 2017 | 126 | 0.04 | Why? |
| Genetic Engineering | 1 | 2018 | 325 | 0.04 | Why? |
| Italy | 1 | 2021 | 38444 | 0.04 | Why? |
| Blood-Brain Barrier | 1 | 2020 | 531 | 0.04 | Why? |
| Liposomes | 1 | 2018 | 334 | 0.04 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.04 | Why? |
| Longitudinal Studies | 2 | 2021 | 9893 | 0.04 | Why? |
| Antigen Presentation | 1 | 2018 | 524 | 0.04 | Why? |
| Lymphocyte Count | 1 | 2007 | 4758 | 0.04 | Why? |
| United Kingdom | 3 | 2021 | 18046 | 0.04 | Why? |
| Expert Testimony | 1 | 2018 | 658 | 0.04 | Why? |
| Sarcoma | 1 | 2018 | 290 | 0.03 | Why? |
| Pancreas | 1 | 2018 | 398 | 0.03 | Why? |
| Central Nervous System | 1 | 2020 | 701 | 0.03 | Why? |
| Cell Communication | 1 | 2016 | 396 | 0.03 | Why? |
| Data Mining | 1 | 2020 | 767 | 0.03 | Why? |
| Predictive Value of Tests | 2 | 2020 | 9537 | 0.03 | Why? |
| Administration, Intravenous | 1 | 2018 | 1115 | 0.03 | Why? |
| Asia | 1 | 2021 | 2399 | 0.03 | Why? |
| Immunophenotyping | 1 | 2018 | 1290 | 0.03 | Why? |
| Cell Membrane | 1 | 2018 | 743 | 0.03 | Why? |
| RNA, Small Interfering | 1 | 2018 | 817 | 0.03 | Why? |
| Oral Health | 1 | 2018 | 401 | 0.03 | Why? |
| Severity of Illness Index | 1 | 2021 | 48226 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2018 | 9335 | 0.03 | Why? |
| Activities of Daily Living | 1 | 2021 | 1530 | 0.03 | Why? |
| Healthy Volunteers | 1 | 2018 | 1444 | 0.03 | Why? |
| Dendritic Cells | 1 | 2020 | 1330 | 0.03 | Why? |
| Surveys and Questionnaires | 1 | 2019 | 43792 | 0.03 | Why? |
| Datasets as Topic | 1 | 2018 | 1404 | 0.03 | Why? |
| Disease-Free Survival | 1 | 2016 | 1654 | 0.03 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.03 | Why? |
| Transcription, Genetic | 1 | 2017 | 1326 | 0.03 | Why? |
| Area Under Curve | 1 | 2018 | 2564 | 0.03 | Why? |
| Drug Monitoring | 1 | 2018 | 1408 | 0.02 | Why? |
| Adolescent | 2 | 2019 | 86841 | 0.02 | Why? |
| RNA, Long Noncoding | 1 | 2014 | 408 | 0.02 | Why? |
| Pilot Projects | 1 | 2021 | 5182 | 0.02 | Why? |
| Child | 1 | 2019 | 70012 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2018 | 2830 | 0.02 | Why? |
| ROC Curve | 1 | 2021 | 6024 | 0.02 | Why? |
| Lymphocyte Activation | 1 | 2018 | 2742 | 0.02 | Why? |
| Temperature | 1 | 2018 | 2305 | 0.02 | Why? |
| Prevalence | 2 | 2020 | 25773 | 0.02 | Why? |
| Molecular Targeted Therapy | 1 | 2017 | 1579 | 0.02 | Why? |
| Canada | 1 | 2021 | 6018 | 0.02 | Why? |
| Mice, Inbred BALB C | 1 | 2018 | 5814 | 0.02 | Why? |
| Public Health Surveillance | 1 | 2021 | 3129 | 0.02 | Why? |
| Interferon Type I | 1 | 2020 | 2789 | 0.02 | Why? |
| Gene Expression | 1 | 2017 | 3332 | 0.02 | Why? |
| Logistic Models | 1 | 2021 | 9089 | 0.02 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 3633 | 0.02 | Why? |
| Adaptive Immunity | 1 | 2018 | 2585 | 0.02 | Why? |
| Cells, Cultured | 1 | 2017 | 5835 | 0.02 | Why? |
| Databases, Factual | 1 | 2020 | 6248 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2021 | 11304 | 0.02 | Why? |
| Lymphocytes | 1 | 2017 | 3056 | 0.02 | Why? |
| Nursing Homes | 1 | 2021 | 4155 | 0.02 | Why? |
| United States | 2 | 2021 | 46150 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2021 | 9091 | 0.02 | Why? |
| Case-Control Studies | 1 | 2021 | 17671 | 0.01 | Why? |
| Immunocompromised Host | 1 | 2018 | 5150 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 11367 | 0.01 | Why? |
| Magnetic Resonance Imaging | 1 | 2018 | 6551 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2020 | 22971 | 0.01 | Why? |
| Socioeconomic Factors | 1 | 2017 | 8495 | 0.01 | Why? |
| Disease Progression | 1 | 2018 | 13580 | 0.01 | Why? |
| Incidence | 1 | 2020 | 25622 | 0.01 | Why? |
| Disease Management | 1 | 2015 | 6841 | 0.01 | Why? |
| Kaplan-Meier Estimate | 1 | 2006 | 4260 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2021 | 21571 | 0.01 | Why? |
| Registries | 1 | 2017 | 12327 | 0.01 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.01 | Why? |
| Cohort Studies | 1 | 2016 | 36005 | 0.01 | Why? |
| Young Adult | 1 | 2020 | 93724 | 0.01 | Why? |
| Forecasting | 1 | 2003 | 4492 | 0.01 | Why? |
| Retrospective Studies | 1 | 2020 | 105322 | 0.01 | Why? |
| Pregnancy | 1 | 2006 | 23879 | 0.00 | Why? |
| Clinical Trials as Topic | 1 | 2003 | 7330 | 0.00 | Why? |
| Time Factors | 1 | 2006 | 31397 | 0.00 | Why? |